A large pharmaceutical company with a digital health technology sought an evidence planning framework to support evidence needs of dual key stakeholders: national European HTA agencies and regional European budget holders. 


In four working sessions with the client, a cross-competency Ascenian team – comprised of HTA methodology experts, funding specialists from sick funds, regional health authorities and regulatory experts – analysed the client’s evidence plans against HTA agencies’ and local budget holders’ existing evidence requirements as well as planned requirements in the future.


The assessment delivered a detailed map of value-driving evidence across 7 EU countries, tailored by stakeholder type (i.e., HTA agencies vs. local budget holders), and identified gaps in the client’s evidence plan and risks related to evolving evidence expectations for digital health technologies. Success hinged on our team’s direct HTA, budget holder and regulatory experience – and the ability to challenge and exchange around the table with the client team.